EP4161639A1 — Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof
Assigned to vTv Therapeutics LLC · Expires 2023-04-12 · 3y expired
What this patent protects
The present disclosure relates to a) crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid ("Compound I "); b) pharmaceutical compositions, comprising one or more crystalline forms of Compound I, and optionally, a p…
USPTO Abstract
The present disclosure relates to a) crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid ("Compound I "); b) pharmaceutical compositions, comprising one or more crystalline forms of Compound I, and optionally, a pharmaceutically acceptable carrier; c) methods of treating a type of diabetes mellitus or other disorders by administering one or more crystalline forms of Compound I; and d) methods for the preparation of crystalline forms of Compound I.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.